⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation

Official Title: A Phase Ib/II Trial of JAB-21822 in Combination With Cetuximab in Patients With Advanced Colorectal Cancer, Small Intestine Cancer and Appendiceal Cancer With KRAS G12C Mutation

Study ID: NCT05194995

Interventions

JAB-21822
Cetuximab

Study Description

Brief Summary: This study is to evaluate the safety, tolerability, pharmacokinetics and antitumor activity of JAB-21822 in combination with cetuximab in patients with advanced colorectal cancer,advanced small intestine cancer and advanced appendiceal cancer with KRAS p.G12C mutation.

Detailed Description: The primary objective of this study is to evaluate the safety and tolerability of JAB-21822 in combination with cetuximab to determine the MTD and RP2D during Dose Escalation phase; then to evaluate preliminary antitumor activity when JAB-21822 is administered in combination with cetuximab during Dose Expansion phase in patients with advanced colorectal cancer,advanced small intestine cancer and advanced appendiceal cancer with KRAS p.G12C mutation.

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Research site31, Beijing, Beijing, China

Research site01, Beijing, Beijing, China

Research site02, Beijing, Beijing, China

Research site12, Beijing, Beijing, China

Research site20, Xiamen, Fujian, China

Research site26, Foshan, Guangdong, China

Research site03, Guangzhou, Guangdong, China

Research site13, Nanning, Guangxi, China

Research site06, Harbin, Heilongjiang, China

Research site05, Zhengzhou, Henan, China

Research site07, Zhengzhou, Henan, China

Research site18, Wuhan, Hubei, China

Research site11, Changsha, Hunan, China

Research site29, Changsha, Hunan, China

Research site09, Nanjing, Jiangsu, China

Research site24, Nanjing, Jiangsu, China

Research site32, Nanjing, Jiangsu, China

Research site08, Nanchang, Jiangxi, China

Research site04, Changchun, Jilin, China

Research site10, Shenyang, Liaoning, China

Research site14, Yinchuan, Ningxia, China

Research site15, Jinan, Shandong, China

Research site16, Linyi, Shandong, China

Research site28, Shanghai, Shanghai, China

Research site22, Xi'an, Shanxi, China

Research site23, Xi'an, Shanxi, China

Research site17, Chengdu, Sichuan, China

Research site19, Hangzhou, Zhejiang, China

Research site21, Hangzhou, Zhejiang, China

Contact Details

Name: Jacobio Pharmaceuticals

Affiliation: Jacobio Pharmaceuticals

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: